Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ono Plans to File Opdivo for 2nd-Line Esophageal Cancer by March-End
November 2, 2018
- Ono Racks Up 19% Revenue Rise on Positive Opdivo Sales
November 2, 2018
- Ribomic Launches PI/IIa Study of Anti-FGF2 Aptamer in US for AMD
November 2, 2018
- Astellas Investing 30 Billion Yen in R&D, Production Facilities Catering to Multiple Modalities
November 1, 2018
- Japan Needs New Pricing Model for Gene Therapies: Astellas Chief
November 1, 2018
- Astellas Sales Rep Number Now at 2,100; Redundancy Program Gets Underway
November 1, 2018
- Daiichi Sankyo Pushes Back Profit Target in 5-Year Plan, Eyes Intensive Investment in Oncology
November 1, 2018
- Chugai Drops Herceptin Patent Suits against Daiichi Sankyo, Pfizer
November 1, 2018
- Daiichi Sankyo’s Half-Year Revenue Fell 4.8% as Generics Sap Olmesartan Sales
November 1, 2018
- Takeda Unveils Post-Acquisition Executive Team, 2 of 20 Members from Shire
November 1, 2018
- Takeda Sees Flat Sales as Brisk US Revenue Offset by Off-Patent Divestiture
November 1, 2018
- Biogen Japan COO Ajai Sulekh Named as New President
November 1, 2018
- Daiichi Sankyo to Discontinue Development of Intradermal Flu Vaccine
November 1, 2018
- Astellas Sales Up 1.1% Driven by Xtandi, OAB Drugs, despite Slump in Japan Business
November 1, 2018
- Sanofi, Daiichi Sankyo to Terminate Marketing Partnership for Hib Vaccine in Japan; Sanofi to Take Over Sales from Jan.
November 1, 2018
- Sumitomo Dainippon Operating Profit Plummets 50% on Drug Price Cut, Generic Erosions
October 31, 2018
- Mitsubishi Tanabe Sales Slip 1.7% as Radicava Boon Fails to Counter Japan Drop
October 31, 2018
- Mitsubishi Tanabe Paints Murky Outlook for US Sales Target on Parkinson’s Development Delay
October 31, 2018
- Nesp Biosame to Hit Japan Market in July-September 2019
October 31, 2018
- Otsuka Pharmaceutical Factory to Jointly Develop Regenerative Medicine Products with Startup
October 31, 2018
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…